sar156597
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01529853)
Timeline
Indications
Mechanism of action
- MAP kinase ERK1INHIBITOR
MAPK3 inhibitor
- MAP kinase ERK2INHIBITOR
MAPK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sar156597
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02921971 | Phase 2 | Nov 1, 2016 | Sanofi |
| NCT02345070 | Phase 2 | May 1, 2015 | Sanofi |
| NCT01529853 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2012 | Sanofi |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 3 | 3 | 1 | 2012 |
1 organizations
Page 1 / 1